http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Dec 2025 16:30:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html <p class="bwalignc"> <b>Enters into North American License and Exclusive Distribution Agreement</b> </p> <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents in sickle cell disease in the U.S., its territories, and Canada in exchange for a upfront payment and a http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Announces+Strategic+Transaction/25791302.html Tue, 30 Dec 2025 16:30:00 -0500 950220 A.06822034 A.14320728 A.16478122 A.50202251 EMMA O.05242772 O.20026344 O.20250741 O.41729403 O.49891921